NYU Technologies In The News

 


Celgene-backed cancer biotech Repare emerges from stealth with $68M

After 18 months being incubated by Versant Ventures, upstart Repare Therapeutics has emerged from stealth mode with an impressive $68 million, backing from Celgene and some big-name execs.The Montreal and Cambridge, Massachusetts, biotech saw founding investor Versant Ventures co-lead the series A round with MPM Capital. They were also joined by other syndicate investors including FTQ, Celgene and BDC Ventures.

Repare’s first disclosed program targets DNA-directed DNA polymerase theta (PolQ), a central component of a pathway that repairs double-strand breaks in cancer cells. New York University School of Medicine has licensed to Repare exclusive rights to drug discovery work targeting PolQ, developed by Agnel Sfeir, Ph.D., with the support of NYU's Office of Therapeutics Alliances. This polymerase is highly expressed in ovarian, breast and a number of other cancers. The first human test for its leading compound is slated for 2019.

Read the full article here:
http://www.fiercebiotech.com/biotech/celgene-backed-cancer-biotech-repare-emerges-from-stealth-68m


BrainScope Launches the Ahead 300 for Objective Assessment of Mild Head Injury, Including Concussion

BrainScope Company, Inc. announced the market release of its flagship Ahead 300 product, and will initiate a limited launch to a select group of thought leadersthrough its Centers of Excellence program later in the first quarter. These institutions will represent a cross-section of market segments including Urgent Care Clinics, Concussion Clinics, Emergency Medicine Departments, and University and Professional Sports. BrainScope will also be selling the Ahead 300 to various branches of the U.S. military and government. BrainScope’s technology is based on intellectual property and research from NYU based on the work of Dr. Leslie Prichep, Professor of Psychiatry at NYU School of Medicine.


Orca Pharmaceuticals and AstraZeneca announce partnership to develop novel drugs for autoimmune disease

Orca Pharmaceuticals, a developer of therapeutics for inflammation, has entered into a partnership agreement with AstraZeneca to develop novel agents against RORgamma, the master regulator for inflammatory Th17 cells. Orca was founded in 2013 and is based on research and intellectual property from Dr. Dan Littman, the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Howard Hughes Medical Institute (HHMI) Investigator.


BeneVir Biopharm closes Series A investment

BeneVir Biopharm, Inc, a developer of cancer immunotherapies, announced it closed a Series A investment by Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. BeneVir Biopharm was founded on NYU intellectual property and research by Dr. Ian Mohr, Professor of Microbiology at the NYU School of Medicine. Dr. Mohr’s research is focused harnessing oncolytic viruses as therapeutics for several types of cancers.


Soligenix acquires oncology program from Hy Biopharma

Soligenix, a clinical stage company, has acquired the rights for SGX301, a Phase 3 asset being developed for cutaneous T-cell lymphoma, from Hy Biopharma. Hy Biopharma was founded on NYU intellectual property and research from Drs. Daniel Meruelo, Professor of Pathology, and Dr. Gad Lavie.


Twitter acquires image search startup Madbits

Twitter has acquired Madbits, a startup founded on work by Dr. Yann LeCun, Silver Professor of Computer Science at NYU’s Courant Institute of Mathematical Sciences.


Janssen Biotherapeutics showcases collaboration with NYU at Annual BIO Convention

At the 2016 Annual BIO Convention in Philadelphia, Janssen Biotherapeutics presented an ongoing collaboration with NYU focused on developing novel therapeutics for Staphylococcus aureus. In addition to the presentation, a video was screened interviewing Dr. Victor Torres, Associate Professor of Microbiology and the NYU Principal Investigator on the project: